

K 121878

NOV 2 2012

510(k) Summary

I. General Information

a. Submitter Information

Submitter's Name and Address	Medtronic, Inc. Medtronic Cardiovascular 8200 Coral Sea Street NE Mounds View, MN 55112
Contact Person	Kari Christianson Senior Regulatory Affairs Specialist Tel: 763-514-9529 FAX: 763-526-8377 Email: kari.j.christianson@medtronic.com
Date of Summary	June 27, 2012
Proprietary Name of Device	Cardioblate® CryoFlex® Surgical Ablation System
Common/Usual Name	Cryosurgical System
Classification Name	Surgical Device, for Ablation of Cardiac Tissue
Classification	Class II, per 21 CFR 878.4350
Product Code:	OCL
Predicate Device	SurgiFrost 7cm, 10cm Cryosurgical Devices (K053436)

Page 1 of 3

II. Device Description

a. System and Components

The Medtronic Cardioblate® CryoFlex® Surgical Ablation Probes, Console, and accessories are used together as a system. The system is composed of the following components:

Components	Model number
Cardioblate CryoFlex Console	65CS1
Cardioblate CryoFlex Console, Refurbished	R65CS1
Cardioblate CryoFlex 7cm Probe	60SF7
Cardioblate CryoFlex 10cm Probe	60SF2
Cardioblate CryoFlex 10S Probe	60SF3
Tank Carrier	65TC1
Tank Regulator	65RAXNA
Tank Regulator, Refurbished	R65RAXNA
Pressure Transducer Cable, 6ft. (1.8m)	67PS6
Gas Hose, 8ft (2.4m)	67H08
Power Cord, North American	671PCNA

b. System Overview

The Medtronic Cardioblate CryoFlex Surgical Ablation System is a cryoablative surgical device that is used in the cryosurgical treatment of cardiac arrhythmias. The system utilizes an argon-based cryogen for fast, controlled freezing.

The Cardioblate CryoFlex Probes are single use, disposable cryoprobes that are designed for use with the system. Each probe has an integrated thermocouple for monitoring temperature at its ablation segment. The probes are supplied sterile, cannot be reused or re-sterilized, and are available in 7cm, 10cm, and 10-S (slightly stiffer) versions.

The probes shaft and ablation segment are made of specially heat-treated stainless steel. The shaft was designed with enough malleability that the surgeon can easily shape it while still maintaining enough stiffness to ensure its stability in the operating field.

The malleable ablation segment has a bellows configuration, which provides kink resistance and thermal performance. A movable insulative sleeve on the shaft allows the surgeon to vary the size of the ablation zone.

The probe has a 3m (10ft) connection hose which is to be handed out of the sterile field to an operating room nurse for connection to the control panel. Note that once the probe is connected to the control panel, it should not be disconnected until the end of the procedure because it cannot be reconnected. The probe is disabled once it is disconnected.

III. Indications for Use

The Cardioblate CryoFlex Surgical Ablation System is intended for minimally invasive cardiac surgical procedures, including the treatment of cardiac arrhythmias. The Cardioblate CryoFlex 7 cm, 10 cm, and 10-S probes plus the Clamp and Surgical Ablation Console freeze target tissue and block the electrical conduction pathways by creating an inflammatory response and cryonecrosis.

There is no change to the indications for use as compared to the predicate device.

IV. Comparison to Predicate Devices

The Medtronic Cardioblate CryoFlex Surgical Ablation system is substantially equivalent to the predicate surgical ablation system, has the same intended use and the same design with the exception of an alternate insulative sheath component on the 7cm, 10cm and 10S models (60SF7, 60SF2, and 60SF3, respectively), and a modified heat exchange component on the 10S model (60SF3).

V. Summary of Performance Data

Verification and validation testing has demonstrated that the Medtronic CryoFlex Surgical Ablation System is substantially equivalent to the predicates.

VI. Conclusion

Based on the accumulated technical information, intended use, verification tests and performance data provided, the Cardioblate CryoFlex Surgical Ablation disposable probes and console are substantially equivalent to the currently marketed predicate devices.

Page 3 of 3



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

Medtronic Inc.
c/o Mr. Kari Christianson
Senior Regulatory Affairs Specialist
8200 Coral Sea Street NE, Mail Stop MVS83
Mounds View, MN 55112

NOV 2 2012

Re: K121878
Trade Name: Cardioblate CryoFlex Surgical Ablation Probes
Regulation Number: 21 CFR 878.4400
Regulation Name: Electrosurgical cutting and coagulation device and accessories
Regulatory Class: Class II (two)
Product Code: OCL
Dated: June 27, 2012
Received: June 28, 2012

Dear Mr. Christianson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucml15809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

K 121878

Indications for Use

510(k) Number (if known):

Device Name: Cardioblate® CryoFlex® Surgical Ablation System

Indications For Use: The Cardioblate CryoFlex Surgical Ablation System is intended for minimally invasive cardiac surgical procedures, including the treatment of cardiac arrhythmias. The Cardioblate CryoFlex 7 cm, 10 cm, and 10-S probes plus the Clamp and Surgical Ablation Console freeze target tissue and block the electrical conduction pathways by creating an inflammatory response and cryonecrosis.

Prescription Use X

AND/OR

Over-The-Counter Use

(Part 21 CFR 801 Subpart D)

(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)

Division of Cardiovascular Devices

Page 1 of

510(k) Number K121878

Page 1 of 1